Information on EC 3.4.17.21 - Glutamate carboxypeptidase II

New: Word Map on EC 3.4.17.21
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Mark a special word or phrase in this record:
Search Reference ID:
Select one or more organisms in this record:
Show additional data
Do not include text mining results
Include (text mining) results (more...)
Include results (AMENDA + additional results, but less precise; more...)


The expected taxonomic range for this enzyme is: Eukaryota

EC NUMBER
COMMENTARY hide
3.4.17.21
-
RECOMMENDED NAME
GeneOntology No.
Glutamate carboxypeptidase II
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
release of an unsubstituted, C-terminal glutamyl residue, typically from Ac-Asp-Glu or folylpoly-gamma-glutamates
show the reaction diagram
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
hydrolysis of peptide bond
PATHWAY
BRENDA Link
KEGG Link
MetaCyc Link
Alanine, aspartate and glutamate metabolism
-
-
Metabolic pathways
-
-
CAS REGISTRY NUMBER
COMMENTARY hide
111070-04-3
-
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
beagle dog
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
cynomolgus monkey
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
Mus musculus C57/Bl
C57/Bl mice
-
-
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
malfunction
metabolism
-
acute exposure to valproic acid, a drug used for bipolar disorder and epilepsy and a known histone deacetylase inhibitor, for 4-6 h increases the glutamate carboxypeptidase II protein level in human astrocyte U-87MG cells but does not have a similar effect after 12-24 h exposure. Valproic acid does not affect the glutamate carboxypeptidase II mRNA expression, but decrease in glutamate carboxypeptidase II protein level by cycloheximide treatment is blocked by valproic acid. The valproic acid-induced increase of glutamate carboxypeptidase II protein level may be dependent on the ubiquitin/proteasome pathway. Valproic acid increases the acetylation of glutamate carboxypeptidase II protein at the lysine residues and facilitates a decrease of the poly-ubiquitinated glutamate carboxypeptidase II level. Similarly, M344, a specific histone deacetylase 1/6 inhibitor, also increases the glutamate carboxypeptidase II protein level
physiological function
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
folyl-(gamma-L-glutamic acid)2 + H2O
folyl-gamma-L-glutamic acid + L-glutamate
show the reaction diagram
-
-
-
-
?
folyl-(gamma-L-glutamic acid)3 + H2O
folyl-(gamma-L-glutamic acid)2 + L-glutamate
show the reaction diagram
-
-
-
-
?
folyl-(gamma-L-glutamic acid)4 + H2O
folyl-(gamma-L-glutamic acid)3 + L-glutamate
show the reaction diagram
-
-
-
-
?
folyl-gamma-L-glutamic acid + H2O
folate + L-glutamate
show the reaction diagram
-
-
-
-
?
folyl-poly-gamma-glutamate + H2O
?
show the reaction diagram
-
cleavage of the C-terminal glutamate
-
-
?
gamma-L-Glu-L-Glu + H2O
L-Glu + L-Glu
show the reaction diagram
-
-
-
-
-
L-Asp-L-Glu + H2O
L-Asp + L-Glu
show the reaction diagram
-
-
-
-
-
L-Glu-L-Glu + H2O
L-Glu + L-Glu
show the reaction diagram
-
-
-
-
-
methotrexate triglutamate + H2O
L-Glu + methotrexate
show the reaction diagram
-
-
-
-
N-acetyl-alpha L-aspartyl-L-glutamate + H2O
N-acetyl-L-aspartate + L-glutamate
show the reaction diagram
-
-
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
show the reaction diagram
N-acetyl-Asp-Glu + H2O
N-acetyl-Asp + Glu
show the reaction diagram
N-Acetyl-L-Asp-L-Glu + H2O
?
show the reaction diagram
N-Acetyl-L-Asp-L-Glu + H2O
N-Acetyl-L-Asp + L-Glu
show the reaction diagram
N-acetyl-L-aspartyl-L-glutamate
N-acetyl-L-aspartate + L-glutamate
show the reaction diagram
-
-
-
-
?
N-acetyl-L-aspartyl-L-glutamate + H2O
L-glutamate + N-acetyl-L-aspartate
show the reaction diagram
N-acetyl-L-aspartyl-L-glutamate + H2O
N-acetyl-L-aspartate + L-glutamate
show the reaction diagram
N-[4-(phenylazo)-benzoyl]-L-glutamyl-gamma-L-glutamic acid + H2O
?
show the reaction diagram
-
-
-
-
?
poly-gamma-glutamate folate + H2O
?
show the reaction diagram
poly-gamma-Glutamylfolate + H2O
L-Glu + gamma-glutamylfolate
show the reaction diagram
-
-
removes sequentially gamma-linked glutamates
-
pteroylpentaglutamate + H2O
L-Glu + pteroylglutamate
show the reaction diagram
-
-
-
-
additional information
?
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
folyl-poly-gamma-glutamate + H2O
?
show the reaction diagram
-
cleavage of the C-terminal glutamate
-
-
?
N-acetyl-alpha L-aspartyl-L-glutamate + H2O
N-acetyl-L-aspartate + L-glutamate
show the reaction diagram
-
-
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
show the reaction diagram
N-acetyl-Asp-Glu + H2O
N-acetyl-Asp + Glu
show the reaction diagram
N-Acetyl-L-Asp-L-Glu + H2O
?
show the reaction diagram
N-acetyl-L-aspartyl-L-glutamate + H2O
L-glutamate + N-acetyl-L-aspartate
show the reaction diagram
N-acetyl-L-aspartyl-L-glutamate + H2O
N-acetyl-L-aspartate + L-glutamate
show the reaction diagram
poly-gamma-glutamate folate + H2O
?
show the reaction diagram
additional information
?
-
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
Br-
-
2 mM, activation
Cl-
-
2 mM, activation
F-
-
100 mM, 20% of the activity compared to Cl-
I-
-
2 mM, activation
K+
-
extracellularly applied K+ increases the enzyme activity in vivo in glial cells and the ventral nerve cord
Mg2+
-
activation
Mn2+
-
activation
NO3-
-
2 mM , activation
Sr2+
-
activation
additional information
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(2S)-2-([hydroxy[2-(4-hydroxyphenyl)ethoxy]phosphoryl]methyl)pentanedioic acid
-
-
(2S)-2-([[2-(4-fluorophenyl)ethoxy](hydroxy)phosphoryl]methyl)pentanedioic acid
-
-
(2S)-2-([[2-(4-[[N-(tert-butoxycarbonyl)glycyl]amino]phenyl)ethoxy](hydroxy)phosphoryl]methyl)pentanedioic acid
-
-
(2S)-2-[([[(1S)-1,3-dicarboxypropyl]amino]carbonyl)amino]pentanedioic acid
-
-
(2S)-2-[([[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]carbonyl)amino]pentanedioic acid
-
the inhibitor has the ability to reduce the perception of inflammatory pain
(2S)-2-[([[(1S)-1-carboxy-2-phenylethyl]amino]carbonyl)amino]pentanedioic acid
-
-
(2S)-2-[([[(1S)-1-carboxy-3-(1H-tetrazol-5-yl)propyl]amino]carbonyl)amino]pentanedioic acid
-
-
(2S)-2-[([[(1S)-1-carboxy-3-(2H-tetrazol-5-yl)propyl]amino]carbonyl)amino]-4-(2H-tetrazol-5-yl)butanoic acid
-
-
(2S)-2-[([[(1S)-3-carboxy-1-(2H-tetrazol-5-yl)propyl]amino]carbonyl)amino]pentanedioic acid
-
-
(2S)-2-[([[(S)-carboxy(4-hydroxyphenyl)methyl]amino]carbonyl)amino]pentanedioic acid
-
-
(2S)-2-[[(2-[4-[(tert-butoxycarbonyl)amino]phenyl]ethoxy)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
-
(2S)-2-[[([(1S)-1-carboxy-3-[1-(2-cyanoethyl)-1H-tetrazol-5-yl]propyl]amino)carbonyl]amino]pentanedioic acid
-
-
(2S)-2-[[([(1S)-3-carboxy-1-[2-(2-cyanoethyl)-2H-tetrazol-5-yl]propyl]amino)carbonyl]amino]pentanedioic acid
-
-
(2S)-2-[[butyl(hydroxy)phosphorothioyl]amino]pentanedioic acid
-
-
(2S)-2-[[ethyl(hydroxy)phosphorothioyl]amino]pentanedioic acid
-
-
(2S)-2-[[hydroxy(2-phenylethoxy)phosphoryl]methyl]pentanedioic acid
-
-
(2S)-2-[[hydroxy(3-phenylpropoxy)phosphoryl]methyl]pentanedioic acid
-
-
(2S)-2-[[hydroxy(methyl)phosphorothioyl]amino]pentanedioic acid
-
-
(2S)-2-[[hydroxy(phenyl)phosphorothioyl]amino]pentanedioic acid
-
-
(2S)-2-[[hydroxy(phenyl)phosphorothioyl]oxy]pentanedioic acid
-
-
(2S)-2-[[hydroxy(phenyl)phosphoryl]amino]pentanedioic acid
-
-
(2S)-2-[[[2-[4-(acetylamino)phenyl]ethoxy](hydroxy)phosphoryl]methyl]pentanedioic acid
-
-
(2S,2'S,4R)-4-benzyl-N,N'-carbonyldiglutamic acid
-
-
(2S,2'S,4R,4'R)-4,4'-dibenzyl-N,N'-carbonyldiglutamic acid
-
-
(2S,2'S,4R,4'R)-N,N'-carbonyl-4,4'-dimethyldiglutamic acid
-
-
(2S,2'S,4S)-N,N'-carbonyl-4-methyldiglutamic acid
-
-
(2S,2'S,4S,4'S)-N,N'-carbonyl-4,4'-dimethyldiglutamic acid
-
-
(2S,3'S)-[[(3'-amino-3'-carboxy-propyl)-hydroxyphosphinoyl]methyl]-pentanedioic acid
-
EPE, a phosphapeptide transition state analog of glutamyl-glutamate
(2S,4R)-2-[([[(1S,3R)-1,3-dicarboxybutyl]amino]carbonyl)amino]-4-methylpentanedioic acid
-
-
(2S,4S)-2-[([[(1S,3S)-1,3-dicarboxybutyl]amino]carbonyl)amino]-4-methylpentanedioic acid
-
-
(4S)-4-[([[(1S)-3-carboxy-1-(2H-tetrazol-5-yl)propyl]amino]carbonyl)amino]-4-(2H-tetrazol-5-yl)butanoic acid
-
-
(9S,13S)-1-(3-iodophenyl)-3,11-dioxo-2,4,10,12-tetraazapentadecane-9,13,15-tricarboxylic acid
-
-
(R)-2-(3-mercaptopropyl)-pentanedioic acid
(R)-2-(hydroxypentafluorophenylmethyl-phosphinoylmethyl)pentanedioic acid
(R)-2-(phosphonomethyl)-pentanedioic acid
(S)-2-(3-((R)-1-carboxy-(2-methylthio)ethyl)ureido)pentanedioic acid
-
DCMC
(S)-2-(3-((R)-1-carboxy-2-(4-fluorobenzylthio)ethyl)ureido)pentanedioic acid
-
DCFBC
(S)-2-(3-((S)-1-carboxy-(4-iodobenzamido)pentyl)ureido)pentanedioic acid
-
DCIBzL
(S)-2-(3-((S)-1-carboxy-2-(4-hydroxy-3-iodophenyl)ethyl)ureido)pentanedioic acid
-
DCIT
(S)-2-(3-((S)-1-carboxy-5-(2-chlorobenzylamino)pentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(2-iodobenzylamino)pentyl)ureido)-pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(3-(4-bromophenyl)ureido)pentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(3-(4-chlorophenyl)ureido)pentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(3-(4-fluorophenyl)ureido)pentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(3-(4-iodophenyl)ureido)pentyl)ureido)pentanedioic acid
(S)-2-(3-((S)-1-carboxy-5-(3-chlorobenzylamino)pentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(3-iodobenzylamino)pentyl)ureido)-pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(3-phenylureido)pentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(4-bromobenzylamino)pentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(4-chlorobenzylamino)pentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(4-fluorobenzylamino)pentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(4-iodobenzylamino)pentyl)ureido)-pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(4-iodobenzylamino)pentyl)ureido)pentanedioic acid
-
i.e. MIP-1072, the compound shows affinity to and uptake into prostate cancer cells, binding analysis, overview
(S)-2-(3-((S)-1-carboxy-5-(4-iodophenylsulfonamido)pentyl)-ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(naphthalen-1-ylmethylamino)pentyl)-ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-5-(benzylamino)-1-carboxypentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-5-amino-1-carboxypentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-(4-iodobenzyl)ureido)pentanedioic acid
-
-
(S)-2-(3-mercaptopropyl)-pentanedioic acid
(S)-2-(hydroxypentafluorophenylmethyl-phosphinoylmethyl)pentanedioic acid
(S)-2-(phosphonomethyl)-pentanedioic acid
(S)-2-[3-((S)-1-carboxy-2-(4-hydroxyphenyl)ethyl)ureido]pentanedioic acid
(S)-2-[3-((S)-1-carboxy-2-phenylethyl)ureido]pentanedioic acid
-
-
(S)-2-[3-((S)-1-carboxy-3-(1H-tetrazol-5-yl)propyl)ureido]pentanedioic acid
-
-
(S)-2-[3-((S)-1-carboxy-3-(1H-tetrazol-5-yl)propyl)ureido]pentanedioinc acid
(S)-2-[3-((S)-1-carboxy-3-(methylsulfanyl)propyl)ureido]pentanedioic acid
(S)-2-[3-((S)-1-carboxy-3-methylbutyl)ureido]pentanedioic acid
(S)-2-[3-((S)-1-carboxy-3-[1-(2-cyanoethyl)-1H-tetrazol-5-yl]propyl)ureido]pentanedioic acid
-
-
(S)-2-[3-((S)-3-carboxy-1-(1H-tetrazol-5-yl)propyl)ureido]pentanedioic acid
-
-
(S)-2-[3-((S)-3-carboxy-1-[1-(2-cyanoethyl)-1H-tetrazol-5-yl]propyl)ureido]pentanedioic acid
-
-
(S)-2-[3-((S)-alpha-carboxy-4-hydroxybenzyl)ureido]pentanedioic acid
-
-
(S)-2-[3-((S)-alpha-carboxybenzyl)ureido]pentanedioic acid
-
-
(S)-2-[3-(S)-(1,3-dicarboxypropyl)ureido]pentanedioinc acid
(S)-alpha-ethylglutamate
-
specific group II metabotropic glutamate receptor antagonist, in vivo activity
(S,S)-4,4'-bis[1-(2-cyanoethyl)-1H-tetrazol-5-yl]-2,2'-ureylenedibutyric acid
-
-
(S,S)-4,4'-bis[1-(2-cyanoethyl)-1H-tetrazol-5-yl]-4,4'-ureylenedibutyric acid
-
-
(S,S)-4,4'-di-(1H-tetrazol-5-yl)-2,2'-ureylenedibutyric acid
-
-
(S,S)-4,4'-di-(1H-tetrazol-5-yl)-4,4'-ureylenedibutyric acid
-
-
(S,S)-N,N'-carbonyl-2,2'-dimethyldiglutamic acid
-
-
(t-Bu)Cys-PSI[C-O]-Glu
-
IC50: 29 nM
(Z)-N-(N-Acetyldehydroaspartyl)-L-Glu
-
-
1,10-phenanthroline
-
1 mM, 90% inhibition
2-(2-carboxy-5-mercaptopentyl)benzoic acid
-
IC50: 1700 nM
2-(3-carbamoylbenzyl)-5-mercaptopentanoic acid
-
IC50: 2200 nM
2-(3-carboxybenyl)succinic acid
-
IC50: 0.015 mM
2-(3-cyanobenzyl)-5-mercaptopentanoic acid
-
IC50: 1800 nM
2-(3-hydroxybenzyl)-3-phosphonopropanoic acid
-
IC50: 508 nM
2-(3-mercaptopropyl)-pentanedioic acid
2-(3-mercaptopropyl)pentanedioic acid
2-(3-sulfanylpropyl)pentanedioic acid
-
i.e. GPI-5693, attenuates cocaine-induced conditioned place preference
2-(phosphonomethyl) pentanedioic acid
-
inhibitor completely blocks N-acetylaspartylglutamate cleavage activity but not Amyloid-beta degradation
2-(phosphonomethyl)-4-(5H-tetrazol-5-yl)butanoic acid
-
IC50: 175 nM
2-(phosphonomethyl)-pentanedioic acid
2-(phosphonomethyl)hexanedioic acid
-
IC50: 185 nM
2-(phosphonomethyl)hexanoic acid
-
IC50: 185 nM
2-(phosphonomethyl)pentanedioic acid
2-(Phosphonomethyl)pentanoate
-
-
2-(phosphonomethyl)succinic acid
-
IC50: 2200 nM
2-([hydroxy[3-(trifluoromethyl)benzyl]phosphoryl]methyl)pentanedioic acid
-
IC50: 55 nM
2-([hydroxy[hydroxy(phenyl)methyl]phosphoryl]methyl)pentanedioic acid
-
IC50: 55 nM
2-([hydroxy[hydroxy(pyridin-4-yl)methyl]phosphoryl]methyl)pentanedioic acid
-
IC50: 10 nM
2-amino-3-(3,5-dioxo[1,2,4]oxadiazolidin-2-yl)propionic acid
-
i.e. quisqualic acid, a glutamate-like inhibitor of GCPIII and GCPII
2-benzyl-3-phosphonopropanoic acid
-
IC50: 548 nM
2-benzyl-5-mercaptopentanoic acid
-
IC50: 1400 nM
2-oxoglutarate
-
0.1 mM, 46% inhibition
2-phosphonomethyl-pentanedoic acid
-
2-PMPA
2-[(hydroxy[[(4-methoxyphenyl)amino]methyl]phosphoryl)methyl]pentanedioic acid
-
IC50: 3 nM
2-[[(2,4-dicarboxybutyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 0.5 nM
2-[[(2-carboxy-3-phenylpropyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 2 nM
2-[[(2-carboxy-4-phenylbutyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 2 nM
2-[[(2-carboxyethyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 1 nM
2-[[(2-carboxypropyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 1.5 nM
2-[[(2-fluorobenzyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 156 nM
2-[[(3,5-difluorobenzyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 49 nM
2-[[(3-aminobenzyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 143 nM
2-[[(3-fluorobenzyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 70 nM
2-[[(4-fluorobenzyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 64 nM
2-[[(anilinomethyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 4 nM
2-[[benzyl(hydroxy)phosphoryl]methyl]pentanedioic acid
2-[[hydroxy(2-phenylethyl)phosphoryl]methyl]pentanedioic acid
2-[[hydroxy(3-nitrobenzyl)phosphoryl]methyl]pentanedioic acid
-
IC50 59 nM
2-[[hydroxy(3-phenylpropyl)phosphoryl]methyl]pentanedioic acid
-
IC50: 230 nM
2-[[hydroxy(4-methoxybenzyl)phosphoryl]methyl]pentanedioic acid
-
IC50: 90 nM
2-[[hydroxy(4-methylbenzyl)phosphoryl]methyl]pentanedioic acid
-
IC50: 68 nM
2-[[hydroxy(pentafluorobenzyl)phosphoryl]methyl]pentanedioic acid
-
IC50: 82 nM. Significantly prevents neurodegeneration in a middle cerebral artery occlusion model of cerebral ischemia. In the chronic constrictive model of neuropathic pain, the inhibitor sifnificantly attenuats the hypersensitivity observed with saline-treated animals
2-[[hydroxy(phenyl)phosphoryl]methyl]pentanedioic acid
-
IC50: 2930 nM
2-[[hydroxy(propyl)phosphoryl]methyl]pentanedioic acid
2-[[[(3-fluorophenyl)(hydroxy)methyl](hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 16 nM
2-[[[(benzylamino)methyl](hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 59 nM
2-[[[3,5-bis(trifluoromethyl)benzyl](hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 55 nM
2-[[[3-(benzyloxy)-2-methyl-3-oxopropyl](hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 95 nM
2-{[2-Carboxy-3-(4-methoxy-phenylamino)-propyl]-hydroxy-phosphinoylmethyl}-pentanedioic acid
-
IC50: 3 nM
3-(1-carboxy-4-mercaptobutoxy)benzoic acid
-
IC50: 14 nM
3-(2-carbamoyl-5-mercaptopentyl)benzoic acid
-
IC50: 640 nM
3-(2-carboxy-3-hydroxycarbamoylpropyl)benzoic acid
-
IC50: 0.015 mM
3-(2-carboxy-3-phosphonopropyl)benzoic acid
-
IC50: 120 nM
3-(2-carboxy-5-mercaptopentyl)benzoic acid
-
IC50: 15 nM
3-(2-carboxy-5-mercaptopentyl)benzoic acid methyl ester
-
IC50: 2700 nM
3-(2-carboxy-5-mercaptosulfanylpentyl)benzoic acid
-
IC50: 0.02 mM
3-(2-carboxy-5-tritylsulfanylpentyl)benzoic acid
-
IC50: 0.02 mM
3-(2-oxotetrahydro-thiopyran-3-yl)propionic acid
-
prodrug of inhibitor 2-(3-mercaptopropyl)pentanedioic acid
3-(3-mercaptopropyl)pentanedioic acid
-
presynaptic action of enzyme inhibition, enzyme inhibition depresses mossy fiber-CA3 synaptic transmission
3-(5-mercapto-2-methoxycarbonylpentyl)benzoic acid
-
IC50: 730 nM
3-[(1-carboxy-4-mercaptobutyl)thio]benzoic acid
-
IC50: 32 nM
3-[2-carboxy-3-(hydroxypentafluorophenylmethylphosphinoyl)propyl]benzoic acid
-
IC50: 2400 nM
4,4'-phosphinicobis(butane-1,3-dicarboxylic acid)
4-(2-carboxy-5-mercaptopentyl)benzoic acid
-
IC50: 63 nM
4-(3-hydroxyphenyl)-2-(phosphonomethyl)butanoic acid
-
IC50: 508 nM
4-cyano-2-(phosphonomethyl)butanoic acid
-
IC50: 335 nM
4-phenyl-2-(phosphonomethyl)butanoic acid
-
IC50: 199 nM
5-oxoheptane-1,3,7-tricarboxylic acid
-
0.1 mM, 35% inhibition
5-oxononane-1,3,7,9-tetracarboxylic acid
-
inhibitor possesses mGluR3 agonist activity
Ala-Glu
-
0.0061 mM, 50% inhibition
Asp-Ala
-
0.1 mM, 26% inhibition
Asp-Asp
-
0.1 mM, 42% inhibition
Asp-Glu
Asp-Phe
-
0.1 mM, 22% inhibition
Asp-PSI[C-O-S]-Glu
-
IC50: 0.0461 mM
Asp-PSI[C-O]-Asp
-
IC50: 0.0038 mM
Asp-PSI[S]-Asp
-
0.1 mM, 42% inhibition
aspartate
-
0.1 mM, 42% inhibition
bestatin
-
0.29 mM, 79% inhibition
Cys-PSI[C-O-S]-Glu
-
IC50: 6.9 nM
cysteate
-
0.1 mM, 40% inhibition
cysteine sulfinate
-
0.1 mM, 42% inhibition
D-Glu-D-Glu
-
0.1 mM, 50% inhibition
D-Glu-PSI[C-O]-D-Glu
-
0.1 mM, 67% inhibition
D-Glu-PSI[C-O]-Glu
-
0.001 mM, 25% inhibition
diazabicycloalkane
diphenyl 2-[[[2-[4-([[7-(diethylamino)-2-oxo-2H-chromen-3-yl]carbamoyl]amino)phenyl]ethoxy](hydroxy)phosphoryl]methyl]pentanedioate
-
-
dithiothreitol
-
1 mM, 94.8% inhibition
DUPA
-
enzyme active site binding structure, docking and modelling, detailed overview
gamma-Glu-Glu
Glu-Asp
-
0.1 mM, 27% inhibition
Glu-Glu
Glu-Glu-Glu
Glu-PSI[C-O-C-O]-Glu
-
0.001 mM, 9% inhibition
Glu-PSI[C-O]-Glu
-
IC50: 47 nM
glutathione
-
i.e. gamma-Glu-Cys-Gly, 0.019 mM, 50% inhibition
Gly-Glu
Gly-Gly-Glu
-
0.00098 mM, 50% inhibition
Gly-PSI[C-O-S]-Glu
-
0.001 mM, 46% inhibition
GPI 5693
-
i.e. (R,S)-2-(3-mercaptopropyl)-pentanedioic acid or 2-MPPA, pharmacokinetics and safety of the NAALADase-inhibitor and its effects on the central nervous system after application in vivo, overview
GPI-16476
-
enantiomer of GPI-5693
GPI-16477
-
enantiomer of GPI-5693
GPI-18431
-
enzyme active site binding structure, docking and modelling, detailed overview
GPI-5693
-
-
GPI5232
Ibotenate
-
0.1 mM, 45% inhibition
iodoacetate
-
1 mM, 38% inhibition
L-2-Amino-4-phosphonobutanoate
-
0.1 mM, 37% inhibition
LY341495
-
-
MOPS
-
-
N-(3,4-Dicarboxybutanoyl)glutamic acid
-
-
N-(Dicarboxymethyl)acetylglutaminic acid
-
-
N-(tert-butoxycarbonyl)glycyl-N-[4-[2-([[(2S)-2,4-dicarboxybutyl](hydroxy)phosphoryl]oxy)ethyl]phenyl]-L-prolinamide
-
-
N-(tert-butoxycarbonyl)glycylglycyl-N-[4-[2-([[(2S)-2,4-dicarboxybutyl](hydroxy)phosphoryl]oxy)ethyl]phenyl]glycinamide
-
-
N-([(1S)-1-carboxy-5-([(4-iodophenyl)carbonyl]amino)pentyl]carbamoyl)-L-glutamic acid
-
P1'-diversified urea-based inhibitor, in complex with enzyme PDB entry 3D7H
N-2-([(1S)-1-carboxy-2-(furan-2-yl)ethyl]carbamoyl)-N-6-(4-iodobenzoyl)-L-lysine
-
P1'-diversified urea-based inhibitor, in complex with enzyme PDB entry 4OC3
N-2-([(1S)-1-carboxybut-3-yn-1-yl]carbamoyl)-N-6-(4-iodobenzoyl)-L-lysine
-
P1'-diversified urea-based inhibitor, in complex with enzyme PDB entry 4OC2
N-Acetyl-Asp-Gln
-
0.1 mM, 49% inhibition
N-Acetyl-Asp-Glu-Asp
-
0.1 mM, 49% inhibition
N-Acetyl-Asp-Ser-Gly
-
0.1 mM, 37% inhibition
N-Acetyl-beta-L-Asp-L-Glu
N-Acetyl-Glu-Asp
-
0.036 mM, 50% inhibition
N-Acetyl-Glu-Glu
-
0.00031 mM, 50% inhibition
N-acetyl-L-Asp
-
0.1 mM, 38% inhibition
N-Acetyl-L-Asp-L-Glu
-
0.00054 mM, 50% inhibition
N-acetyl-L-Glu
-
0.058 mM, 50% inhibition
N-Fumaryl-L-Glu
-
-
N-Succinyl-L-Glu
-
-
N-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]carbamoyl]-L-glutamic acid
N-[[(1S)-1-carboxy-3-(methylsulfanyl)propyl]carbamoyl]-L-glutamic acid
N-[[(1S)-1-carboxy-3-methylbutyl]carbamoyl]-L-glutamic acid
Phe-Glu
-
0.077 mM, 50% inhibition
pteroylglutamic acid
-
-
puromycin
-
0.5 mM, 55% inhibition
pyroglutamate
-
0.1 mM, 27% inhibition
pyropheophorbide-a conjugate
-
i.e. Ppa-2 conjugate, non-specificity of unconjugated Ppa, conjugation of a peptidomimetic inhibitor of PSMA to the porphyrinic PS, pyropheophorbide-a gives
quinolinate
-
0.1 mM, 41% inhibition
Quisqualic acid
S-2-((2-(S-4-(4-18F-fluorobenzamido)-4-carboxybutanamido)-S-2-carboxyethoxy)hydroxyphosphorylamino)-pentanedioic acid
-
-
S-2-((2-(S-4-amino-4-carboxybutanamido)-S-2-carboxyethoxy)-hydroxyphosphorylamino)-pentanedioic acid
-
phosphoramidate
Serine O-sulfate
-
0.042 mM, 50% inhibition
t-BuNHC(O)-Glu
-
0.001 mM, 10% inhibition
Tyr-Glu
-
0.1 mM, 45% inhibition
VA-033
Val-Glu-Glu
-
0.036 mM, 50% inhibition
ZJ-43
-
i.e. (S)-2-[3-((S)-1-carboxy-3-methylbutyl)ureido]pentanedioic acid, the inhibitor enhances extracellular NAAG levels and reduces extracellular levels of amino acids neurotransmitter following traumatic brain injury in vivo
ZJ43
-
i.e. (S)-2-[3-((S)-1-carboxy-3-methylbutyl)ureido]pentanedioic acid
[HO2C(CH2)2CH(CO2H)CH2]2P(O)(OH)
-
-
additional information
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
dynorphin A
-
activates glutamate production in the spinal cord
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.000066 - 0.000334
N-acetyl-alpha-L-aspartyl-L-glutamate
130
N-acetyl-Asp-Glu
-
pH 7.4, 37C
0.00014 - 540
N-Acetyl-L-Asp-L-Glu
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
4
N-acetyl-Asp-Glu
Homo sapiens
-
pH 7.4, 37C
1
N-acetyl-L-aspartyl-L-glutamate
Homo sapiens
-
-
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.000008
(2S)-2-[([[(1S)-1,3-dicarboxypropyl]amino]carbonyl)amino]pentanedioic acid
-
pH 7.4, 37C
0.000003
(2S)-2-[([[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]carbonyl)amino]pentanedioic acid
-
pH 7.4, 37C
0.000012
(2S)-2-[([[(1S)-1-carboxy-2-phenylethyl]amino]carbonyl)amino]pentanedioic acid
-
pH 7.4, 37C
0.0000009
(2S)-2-[([[(1S)-1-carboxy-3-(1H-tetrazol-5-yl)propyl]amino]carbonyl)amino]pentanedioic acid
-
pH 7.4, 37C
0.0000149
(2S)-2-[([[(1S)-1-carboxy-3-(2H-tetrazol-5-yl)propyl]amino]carbonyl)amino]-4-(2H-tetrazol-5-yl)butanoic acid
-
pH 7.4, 37C
0.000335
(2S)-2-[([[(1S)-3-carboxy-1-(2H-tetrazol-5-yl)propyl]amino]carbonyl)amino]pentanedioic acid
-
pH 7.4, 37C
0.0000059
(2S)-2-[([[(S)-carboxy(4-hydroxyphenyl)methyl]amino]carbonyl)amino]pentanedioic acid
-
pH 7.4, 37C
0.0000053
(2S)-2-[[([(1S)-1-carboxy-3-[1-(2-cyanoethyl)-1H-tetrazol-5-yl]propyl]amino)carbonyl]amino]pentanedioic acid
-
pH 7.4, 37C
0.002711
(2S)-2-[[([(1S)-3-carboxy-1-[2-(2-cyanoethyl)-2H-tetrazol-5-yl]propyl]amino)carbonyl]amino]pentanedioic acid
-
pH 7.4, 37C
0.000104
(2S)-2-[[butyl(hydroxy)phosphorothioyl]amino]pentanedioic acid
-
pH 7.4, 37C
0.00109
(2S)-2-[[ethyl(hydroxy)phosphorothioyl]amino]pentanedioic acid
-
pH 7.4, 37C
0.000719
(2S)-2-[[hydroxy(methyl)phosphorothioyl]amino]pentanedioic acid
-
pH 7.4, 37C
0.00639
(2S)-2-[[hydroxy(phenyl)phosphorothioyl]amino]pentanedioic acid
-
pH 7.4, 37C
0.0146
(2S)-2-[[hydroxy(phenyl)phosphorothioyl]oxy]pentanedioic acid
-
pH 7.4, 37C
0.00111
(2S)-2-[[hydroxy(phenyl)phosphoryl]amino]pentanedioic acid
-
pH 7.4, 37C
0.000095 - 0.0000953
(2S,2'S,4R)-4-benzyl-N,N'-carbonyldiglutamic acid
0.000392
(2S,2'S,4R,4'R)-4,4'-dibenzyl-N,N'-carbonyldiglutamic acid
-
pH 7.4, 37C; pH 7.4, 37C, recombinant enzyme
0.00129
(2S,2'S,4R,4'R)-N,N'-carbonyl-4,4'-dimethyldiglutamic acid
-
pH 7.4, 37C, recombinant enzyme
0.000014 - 0.0000144
(2S,2'S,4S)-N,N'-carbonyl-4-methyldiglutamic acid
0.00111
(2S,2'S,4S,4'S)-N,N'-carbonyl-4,4'-dimethyldiglutamic acid
-
pH 7.4, 37C, recombinant enzyme
0.0000129 - 0.0000346
(2S,3'S)-[[(3'-amino-3'-carboxy-propyl)-hydroxyphosphinoyl]methyl]-pentanedioic acid
0.001285
(2S,4R)-2-[([[(1S,3R)-1,3-dicarboxybutyl]amino]carbonyl)amino]-4-methylpentanedioic acid
-
pH 7.4, 37C
0.001109
(2S,4S)-2-[([[(1S,3S)-1,3-dicarboxybutyl]amino]carbonyl)amino]-4-methylpentanedioic acid
-
pH 7.4, 37C
0.004388
(4S)-4-[([[(1S)-3-carboxy-1-(2H-tetrazol-5-yl)propyl]amino]carbonyl)amino]-4-(2H-tetrazol-5-yl)butanoic acid
-
pH 7.4, 37C
0.0000015
(S)-2-(3-((S)-1-carboxy-2-(4-hydroxy-3-iodophenyl)ethyl)ureido)pentanedioic acid
-
-
0.00000024
(S)-2-(3-((S)-1-carboxy-5-(3-(4-iodophenyl)ureido)pentyl)ureido)pentanedioic acid
-
-
0.0000046
(S)-2-(3-((S)-1-carboxy-5-(4-iodobenzylamino)pentyl)ureido)pentanedioic acid
-
-
0.000003
(S)-2-[3-((S)-1-carboxy-2-(4-hydroxyphenyl)ethyl)ureido]pentanedioic acid
-
pH 7.4, 37C, recombinant enzyme
0.000012
(S)-2-[3-((S)-1-carboxy-2-phenylethyl)ureido]pentanedioic acid
-
pH 7.4, 37C, recombinant enzyme
0.0000009
(S)-2-[3-((S)-1-carboxy-3-(1H-tetrazol-5-yl)propyl)ureido]pentanedioic acid
-
pH 7.4, 37C, recombinant enzyme
0.0000053
(S)-2-[3-((S)-1-carboxy-3-[1-(2-cyanoethyl)-1H-tetrazol-5-yl]propyl)ureido]pentanedioic acid
-
pH 7.4, 37C, recombinant enzyme
0.000335
(S)-2-[3-((S)-3-carboxy-1-(1H-tetrazol-5-yl)propyl)ureido]pentanedioic acid
-
pH 7.4, 37C, recombinant enzyme
0.00271
(S)-2-[3-((S)-3-carboxy-1-[1-(2-cyanoethyl)-1H-tetrazol-5-yl]propyl)ureido]pentanedioic acid
-
pH 7.4, 37C, recombinant enzyme
0.0000059
(S)-2-[3-((S)-alpha-carboxy-4-hydroxybenzyl)ureido]pentanedioic acid
-
pH 7.4, 37C, recombinant enzyme
0.0000021
(S)-2-[3-((S)-alpha-carboxybenzyl)ureido]pentanedioic acid
-
pH 7.4, 37C; pH 7.4, 37C, recombinant enzyme
0.000008
(S)-2-[3-(S)-(1,3-dicarboxypropyl)ureido]pentanedioinc acid
-
pH 7.4, 37C, recombinant enzyme
0.00443 - 0.004434
(S,S)-4,4'-bis[1-(2-cyanoethyl)-1H-tetrazol-5-yl]-2,2'-ureylenedibutyric acid
1
(S,S)-4,4'-bis[1-(2-cyanoethyl)-1H-tetrazol-5-yl]-4,4'-ureylenedibutyric acid
-
above, pH 7.4, 37C, recombinant enzyme
0.000015
(S,S)-4,4'-di-(1H-tetrazol-5-yl)-2,2'-ureylenedibutyric acid
-
pH 7.4, 37C, recombinant enzyme
0.00439
(S,S)-4,4'-di-(1H-tetrazol-5-yl)-4,4'-ureylenedibutyric acid
-
pH 7.4, 37C, recombinant enzyme
0.000939
(S,S)-N,N'-carbonyl-2,2'-dimethyldiglutamic acid
-
pH 7.4, 37C; pH 7.4, 37C, recombinant enzyme
0.00003
2-(3-mercaptopropyl)-pentanedioic acid
-
-
0.0000002 - 0.0000014
2-(phosphonomethyl)-pentanedioic acid
0.0000014
2-(phosphonomethyl)pentanedioic acid
-
pH 7.4, 37C
0.00023 - 0.00102
2-amino-3-(3,5-dioxo[1,2,4]oxadiazolidin-2-yl)propionic acid
0.061
Ala-Glu
-
-
0.0024
Asp-Glu
-
-
0.1
D-Glu-D-Glu
-
-
0.000008
DUPA
-
-
0.095
gamma-Glu-Glu
-
-
0.00075
Glu-Glu
-
-
0.062
Glu-Glu-Glu
-
-
0.019
glutathione
-
i.e. gamma-Glu-Cys-Gly
0.008
Gly-Glu
-
-
0.00098
Gly-Gly-Glu
-
-
0.00003
GPI-18431
-
-
0.27 - 0.428
L-Glu
0.00000001
N-([(1S)-1-carboxy-5-([(4-iodophenyl)carbonyl]amino)pentyl]carbamoyl)-L-glutamic acid
-
pH not specified in the publication, temperature not specified in the publication
0.0000053
N-2-([(1S)-1-carboxy-2-(furan-2-yl)ethyl]carbamoyl)-N-6-(4-iodobenzoyl)-L-lysine
0.036
N-Acetyl-Glu-Asp
-
-
0.00031
N-Acetyl-Glu-Glu
-
-
0.00054
N-Acetyl-L-Asp-L-Glu
-
-
0.058
N-acetyl-L-Glu
-
-
0.0000149
N-[[(1S)-1-carboxy-3-(1H-tetrazol-5-yl)propyl]carbamoyl]-L-glutamic acid
-
pH 7.4, 37C
0.077
Phe-Glu
-
-
0.042
Serine O-sulfate
-
-
0.036
Val-Glu-Glu
-
-
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.0000002
(2S)-2-([hydroxy[2-(4-hydroxyphenyl)ethoxy]phosphoryl]methyl)pentanedioic acid
Homo sapiens
-
-
0.0003
(2S)-2-([[2-(4-fluorophenyl)ethoxy](hydroxy)phosphoryl]methyl)pentanedioic acid
Homo sapiens
-
-
0.0000007
(2S)-2-([[2-(4-[[N-(tert-butoxycarbonyl)glycyl]amino]phenyl)ethoxy](hydroxy)phosphoryl]methyl)pentanedioic acid
Homo sapiens
-
-
0.0000001
(2S)-2-[[(2-[4-[(tert-butoxycarbonyl)amino]phenyl]ethoxy)(hydroxy)phosphoryl]methyl]pentanedioic acid
Homo sapiens
-
-
0.0000008
(2S)-2-[[hydroxy(2-phenylethoxy)phosphoryl]methyl]pentanedioic acid
Homo sapiens
-
-
0.000004
(2S)-2-[[hydroxy(3-phenylpropoxy)phosphoryl]methyl]pentanedioic acid
0.000018
(9S,13S)-1-(3-iodophenyl)-3,11-dioxo-2,4,10,12-tetraazapentadecane-9,13,15-tricarboxylic acid
Homo sapiens
-
-
0.0014
(R)-2-(hydroxypentafluorophenylmethyl-phosphinoylmethyl)pentanedioic acid
Homo sapiens
-
40fold less potent than the S-isomer, IC50: 0.0014 mM
0.00003
(R)-2-(phosphonomethyl)-pentanedioic acid
Homo sapiens
-
less potent than the S-isomer, IC50: 0.000030 mM
0.000017
(S)-2-(3-((R)-1-carboxy-(2-methylthio)ethyl)ureido)pentanedioic acid
Homo sapiens
-
-
0.000014
(S)-2-(3-((R)-1-carboxy-2-(4-fluorobenzylthio)ethyl)ureido)pentanedioic acid
Homo sapiens
-
-
0.00000006
(S)-2-(3-((S)-1-carboxy-(4-iodobenzamido)pentyl)ureido)pentanedioic acid
Homo sapiens
-
-
0.0000005
(S)-2-(3-((S)-1-carboxy-2-(4-hydroxy-3-iodophenyl)ethyl)ureido)pentanedioic acid
Homo sapiens
-
-
0.000245
(S)-2-(3-((S)-1-carboxy-5-(2-chlorobenzylamino)pentyl)ureido)pentanedioic acid
Homo sapiens
-
-
0.000037
(S)-2-(3-((S)-1-carboxy-5-(2-iodobenzylamino)pentyl)ureido)-pentanedioic acid
Homo sapiens
-
-
0.000002
(S)-2-(3-((S)-1-carboxy-5-(3-(4-bromophenyl)ureido)pentyl)ureido)pentanedioic acid
Homo sapiens
-
-
0.000004
(S)-2-(3-((S)-1-carboxy-5-(3-(4-chlorophenyl)ureido)pentyl)ureido)pentanedioic acid
Homo sapiens
-
-
0.000003
(S)-2-(3-((S)-1-carboxy-5-(3-(4-fluorophenyl)ureido)pentyl)ureido)pentanedioic acid
Homo sapiens
-
-
0.00001
(S)-2-(3-((S)-1-carboxy-5-(3-(4-iodophenyl)ureido)pentyl)ureido)pentanedioic acid
Homo sapiens
-
-
0.000277
(S)-2-(3-((S)-1-carboxy-5-(3-chlorobenzylamino)pentyl)ureido)pentanedioic acid
Homo sapiens
-
-
0.000443
(S)-2-(3-((S)-1-carboxy-5-(3-iodobenzylamino)pentyl)ureido)-pentanedioic acid
Homo sapiens
-
-
0.000012
(S)-2-(3-((S)-1-carboxy-5-(3-phenylureido)pentyl)ureido)pentanedioic acid
Homo sapiens
-
-
0.000043
(S)-2-(3-((S)-1-carboxy-5-(4-bromobenzylamino)pentyl)ureido)pentanedioic acid
Homo sapiens
-
-
0.000002
(S)-2-(3-((S)-1-carboxy-5-(4-chlorobenzylamino)pentyl)ureido)pentanedioic acid
Homo sapiens
-
-
0.0012
(S)-2-(3-((S)-1-carboxy-5-(4-fluorobenzylamino)pentyl)ureido)pentanedioic acid
Homo sapiens
-
-
0.000022
(S)-2-(3-((S)-1-carboxy-5-(4-iodobenzylamino)pentyl)ureido)-pentanedioic acid
Homo sapiens
-
-
0.00001
(S)-2-(3-((S)-1-carboxy-5-(4-iodophenylsulfonamido)pentyl)-ureido)pentanedioic acid
Homo sapiens
-
-
0.000154
(S)-2-(3-((S)-1-carboxy-5-(naphthalen-1-ylmethylamino)pentyl)-ureido)pentanedioic acid
Homo sapiens
-
-
0.00296
(S)-2-(3-((S)-5-(benzylamino)-1-carboxypentyl)ureido)pentanedioic acid
Homo sapiens
-
-
0.000498
(S)-2-(3-((S)-5-amino-1-carboxypentyl)ureido)pentanedioic acid
Homo sapiens
-
-
0.003
(S)-2-(3-(4-iodobenzyl)ureido)pentanedioic acid
Homo sapiens
-
-
0.000034
(S)-2-(hydroxypentafluorophenylmethyl-phosphinoylmethyl)pentanedioic acid
Homo sapiens
-
40fold more potent than the R-isomer, IC50: 0.000034 mM
0.0000001
(S)-2-(phosphonomethyl)-pentanedioic acid
Homo sapiens
-
more potent than the R-isomer, IC50: 0.0000001 mM
0.000029
(t-Bu)Cys-PSI[C-O]-Glu
Rattus norvegicus
-
IC50: 29 nM
0.0017
2-(2-carboxy-5-mercaptopentyl)benzoic acid
Homo sapiens
-
IC50: 1700 nM
0.0022
2-(3-carbamoylbenzyl)-5-mercaptopentanoic acid
Homo sapiens
-
IC50: 2200 nM
0.015
2-(3-carboxybenyl)succinic acid
Homo sapiens
-
IC50: 0.015 mM
0.0018
2-(3-cyanobenzyl)-5-mercaptopentanoic acid
Homo sapiens
-
IC50: 1800 nM
0.000508
2-(3-hydroxybenzyl)-3-phosphonopropanoic acid
Rattus norvegicus
-
IC50: 508 nM
0.00009
2-(3-mercaptopropyl)-pentanedioic acid
0.000175
2-(phosphonomethyl)-4-(5H-tetrazol-5-yl)butanoic acid
Rattus norvegicus
-
IC50: 175 nM
0.00000674 - 0.000094
2-(phosphonomethyl)-pentanedioic acid
0.000185
2-(phosphonomethyl)hexanedioic acid
0.0000003 - 0.0000051
2-(phosphonomethyl)pentanedioic acid
0.0022
2-(phosphonomethyl)succinic acid
Rattus norvegicus
-
IC50: 2200 nM
0.000055
2-([hydroxy[3-(trifluoromethyl)benzyl]phosphoryl]methyl)pentanedioic acid
0.00001
2-([hydroxy[hydroxy(pyridin-4-yl)methyl]phosphoryl]methyl)pentanedioic acid
Rattus norvegicus
-
IC50: 10 nM
0.000548
2-benzyl-3-phosphonopropanoic acid
Rattus norvegicus
-
IC50: 548 nM
0.0014
2-benzyl-5-mercaptopentanoic acid
Homo sapiens
-
IC50: 1400 nM
0.000003
2-[(hydroxy[[(4-methoxyphenyl)amino]methyl]phosphoryl)methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 3 nM
0.0000005
2-[[(2,4-dicarboxybutyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 0.5 nM
0.000002
2-[[(2-carboxy-3-phenylpropyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
0.000001
2-[[(2-carboxyethyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 1 nM
0.0000015
2-[[(2-carboxypropyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 1.5 nM
0.000156
2-[[(2-fluorobenzyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 156 nM
0.000049
2-[[(3,5-difluorobenzyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 49 nM
0.000143
2-[[(3-aminobenzyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 143 nM
0.00007
2-[[(3-fluorobenzyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 70 nM
0.000064
2-[[(4-fluorobenzyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 64 nM
0.000004
2-[[(anilinomethyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 4 nM
0.000053 - 0.00007
2-[[benzyl(hydroxy)phosphoryl]methyl]pentanedioic acid
0.000149 - 0.00015
2-[[hydroxy(2-phenylethyl)phosphoryl]methyl]pentanedioic acid
0.000059
2-[[hydroxy(3-nitrobenzyl)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50 59 nM
0.00023
2-[[hydroxy(3-phenylpropyl)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 230 nM
0.00009
2-[[hydroxy(4-methoxybenzyl)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 90 nM
0.000068
2-[[hydroxy(4-methylbenzyl)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 68 nM
0.000082
2-[[hydroxy(pentafluorobenzyl)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 82 nM. Significantly prevents neurodegeneration in a middle cerebral artery occlusion model of cerebral ischemia. In the chronic constrictive model of neuropathic pain, the inhibitor sifnificantly attenuats the hypersensitivity observed with saline-
0.00293
2-[[hydroxy(phenyl)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 2930 nM
0.00036 - 0.00056
2-[[hydroxy(propyl)phosphoryl]methyl]pentanedioic acid
0.000016
2-[[[(3-fluorophenyl)(hydroxy)methyl](hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 16 nM
0.000059
2-[[[(benzylamino)methyl](hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 59 nM
0.000055
2-[[[3,5-bis(trifluoromethyl)benzyl](hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 55 nM
0.000095
2-[[[3-(benzyloxy)-2-methyl-3-oxopropyl](hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus
-
IC50: 95 nM
0.000003
2-{[2-Carboxy-3-(4-methoxy-phenylamino)-propyl]-hydroxy-phosphinoylmethyl}-pentanedioic acid
Rattus norvegicus
-
IC50: 3 nM
0.000014
3-(1-carboxy-4-mercaptobutoxy)benzoic acid
Homo sapiens
-
IC50: 14 nM
0.00064
3-(2-carbamoyl-5-mercaptopentyl)benzoic acid
Homo sapiens
-
IC50: 640 nM
0.015
3-(2-carboxy-3-hydroxycarbamoylpropyl)benzoic acid
Homo sapiens
-
IC50: 0.015 mM
0.00012
3-(2-carboxy-3-phosphonopropyl)benzoic acid
Homo sapiens
-
IC50: 120 nM
0.000015
3-(2-carboxy-5-mercaptopentyl)benzoic acid
Homo sapiens
-
IC50: 15 nM
0.0027
3-(2-carboxy-5-mercaptopentyl)benzoic acid methyl ester
Homo sapiens
-
IC50: 2700 nM
0.02
3-(2-carboxy-5-mercaptosulfanylpentyl)benzoic acid
0.002
3-(2-oxotetrahydro-thiopyran-3-yl)propionic acid
Rattus norvegicus
-
pH not specified in the publication, temperature not specified in the publication
0.00073
3-(5-mercapto-2-methoxycarbonylpentyl)benzoic acid
Homo sapiens
-
IC50: 730 nM
0.000032
3-[(1-carboxy-4-mercaptobutyl)thio]benzoic acid
Homo sapiens
-
IC50: 32 nM
0.0024
3-[2-carboxy-3-(hydroxypentafluorophenylmethylphosphinoyl)propyl]benzoic acid
Homo sapiens
-
IC50: 2400 nM
0.000063
4-(2-carboxy-5-mercaptopentyl)benzoic acid
Homo sapiens
-
IC50: 63 nM
0.000508
4-(3-hydroxyphenyl)-2-(phosphonomethyl)butanoic acid
Rattus norvegicus
-
IC50: 508 nM
0.000335
4-cyano-2-(phosphonomethyl)butanoic acid
Rattus norvegicus
-
IC50: 335 nM
0.000199
4-phenyl-2-(phosphonomethyl)butanoic acid
Rattus norvegicus
-
IC50: 199 nM
0.0461
Asp-PSI[C-O-S]-Glu
Rattus norvegicus
-
IC50: 0.0461 mM
0.0038
Asp-PSI[C-O]-Asp
Rattus norvegicus
-
IC50: 0.0038 mM
0.0000069
Cys-PSI[C-O-S]-Glu
Rattus norvegicus
-
IC50: 6.9 nM
0.000002
diphenyl 2-[[[2-[4-([[7-(diethylamino)-2-oxo-2H-chromen-3-yl]carbamoyl]amino)phenyl]ethoxy](hydroxy)phosphoryl]methyl]pentanedioate
Homo sapiens
-
-
0.000047
Glu-PSI[C-O]-Glu
Rattus norvegicus
-
IC50: 47 nM
0.000007
N-(tert-butoxycarbonyl)glycyl-N-[4-[2-([[(2S)-2,4-dicarboxybutyl](hydroxy)phosphoryl]oxy)ethyl]phenyl]-L-prolinamide
Homo sapiens
-
-
0.000008
N-(tert-butoxycarbonyl)glycylglycyl-N-[4-[2-([[(2S)-2,4-dicarboxybutyl](hydroxy)phosphoryl]oxy)ethyl]phenyl]glycinamide
Homo sapiens
-
-
0.000102
pyropheophorbide-a conjugate
Homo sapiens
-
pH 7.4, 37C
0.000014
S-2-((2-(S-4-(4-18F-fluorobenzamido)-4-carboxybutanamido)-S-2-carboxyethoxy)hydroxyphosphorylamino)-pentanedioic acid
Homo sapiens
-
-
0.00000068
S-2-((2-(S-4-amino-4-carboxybutanamido)-S-2-carboxyethoxy)-hydroxyphosphorylamino)-pentanedioic acid
Homo sapiens
-
-
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
0.000000054 - 0.000000148
-
-
0.0000036
-
-
additional information
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
5
-
second optimum at pH 8
7.5
assay at
7.7
-
assay at, recombinant enzyme
8
-
second optimum at pH 5
pH RANGE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
6 - 7.4
-
more than 50% of maximal activity in this range
additional information
pH profile
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
TEMPERATURE RANGE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
25 - 80
-
more than 50% of maximal activity in this range
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE
-
quantitative expression analysis
Manually annotated by BRENDA team
-
prostate cancer cell line
Manually annotated by BRENDA team
-
cortical cells dissociated in cell culture
Manually annotated by BRENDA team
-
ventricular, lumbar, and subarachnoid
Manually annotated by BRENDA team
-
primary cancer
Manually annotated by BRENDA team
-
dorsal root ganglia
Manually annotated by BRENDA team
-
PSMA is expressed in the neovasculature of multiple nonprostatic solid tumors, it shows a unique expression pattern limited to tumor-associated endothelial cells. Expression in liver metastasis from colorectal cancers and lymph node metastasis from colorectal cancers
Manually annotated by BRENDA team
GCPIII
Manually annotated by BRENDA team
-
very low enzyme expression level
Manually annotated by BRENDA team
-
high expression level
Manually annotated by BRENDA team
-
higher level in patients with prostrate cancer, lower levels in healthy male donors
Manually annotated by BRENDA team
additional information
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY hide
GeneOntology No.
LITERATURE
SOURCE
-
associated with
Manually annotated by BRENDA team
-
synaptoneurosome
-
Manually annotated by BRENDA team
additional information
-
Vinca alkaloids destabilize the microtubules leading to basolateral expression of the enzyme and its integration into the basolateral membrane
-
Manually annotated by BRENDA team